Publication: Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature
Issued Date
2021-01-01
Resource Type
ISSN
15298019
13960296
13960296
Other identifier(s)
2-s2.0-85096849659
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatologic Therapy. Vol.34, No.1 (2021)
Suggested Citation
Chuda Rujitharanawong, Leena Chularojanamontri, Suphattra Trakanwittayarak, Sumruay Pinkaew, Sasipha Nuttawong Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature. Dermatologic Therapy. Vol.34, No.1 (2021). doi:10.1111/dth.14569 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78879
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature
Other Contributor(s)
Abstract
Livedoid vasculopathy (LV) is an uncommon, chronic, and recurrent thrombo-occlusive vascular disorder. Data specific to LV in Thai population remains scarce. This study aimed to evaluate the clinical course and treatment outcomes of LV in Thai patients, and to perform a literature review for studies that reported on anticoagulant treatment in LV. Seventy-four patients with a mean age of 37.6 ± 14.7 years were included. The female to male ratio was 5.2:1, and the median follow-up was 10.5 months. Most patients had primary LV disorder. Forty-eight patients were improved with treatments, with a median duration of 11.4 months. Combination treatments were commonly used, including anti-inflammatories, antiplatelets, and immunosuppressants. Add-on therapy with anticoagulant or psoralen plus ultraviolet-A (PUVA) led to disease improvement in a majority of the patients treated. Kaplan-Meier analysis demonstrated that 38.5%, 53.7%, and 57.9% would have disease improvement at 1, 2, and 3 years, respectively. Of 39 studies (n = 219) that reported on anticoagulant treatment in LV, anticoagulant drug was used as monotherapy in 104 patients. The mean duration of anticoagulant treatment was 7.2 ± 3.8 months, which led to disease improvement in 97 patients (93.3%). Bleeding side effect was found in 9 patients (8.7%). The highest incidence of LV was found among females aged 30 to 40 years. Combination therapy with anti-inflammatory drugs, antiplatelet drugs, and immunosuppressants led to disease improvement. The observed efficacy of add-on PUVA or anticoagulant is promising and should be further investigated. Further studies are needed to guide the development of an LV management guideline.